Trial Profile
A Double Blind, Randomized Placebo Controlled Crossover Multiple Dose Study of LJN452 to Assess Safety, Tolerability and Efficacy in Patients With Primary Bile Acid Diarrhea (pBAD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2020
Price :
$35
*
At a glance
- Drugs Tropifexor (Primary)
- Indications Primary bile acid malabsorption
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 23 Jul 2020 Status changed to discontinued, according to results published in the Alimentary Pharmacology and Therapeutics
- 23 Jul 2020 Results published in the Alimentary Pharmacology and Therapeutics
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.